Published in Cancer Res on August 01, 1994
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer (2007) 1.87
Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. J Control Release (2011) 1.59
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer (1999) 1.50
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol (2004) 1.23
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs (2010) 1.01
Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One (2012) 0.95
Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. J Clin Pathol (2005) 0.89
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. Br J Cancer (2009) 0.89
Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J Med Chem (2007) 0.83
Structural characterization of new deoxycytidine kinase inhibitors rationalizes the affinity-determining moieties of the molecules. Acta Crystallogr D Biol Crystallogr (2013) 0.82
The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines. BMC Cancer (2006) 0.82
Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Invest New Drugs (2009) 0.79
Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs (2013) 0.78
The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol (2012) 0.78
Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer. Clin Cancer Res (2014) 0.77
Cytotoxicity of sphingoid marine compound analogs in mono- and multilayered solid tumor cell cultures. Invest New Drugs (2006) 0.76
Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncol Lett (2016) 0.75
An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone. Biochem Pharmacol (2007) 0.75
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst (2001) 4.27
Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods (1984) 4.15
Mammalian deoxyribonucleoside kinases. Pharmacol Ther (1995) 3.31
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Myrosinase: gene family evolution and herbivore defense in Brassicaceae. Plant Mol Biol (2000) 3.15
Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med (1989) 3.03
Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet (2001) 2.91
Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med (1986) 2.84
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst (2009) 2.83
Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut (1996) 2.79
The drug resistance-related protein LRP is the human major vault protein. Nat Med (1995) 2.78
Reversible thyroid dysfunction during treatment with GM-CSF. Lancet (1991) 2.77
Studies in alpha 1-antitrypsin deficiency. Acta Med Scand Suppl (1965) 2.77
The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet (2001) 2.71
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A (1994) 2.71
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol (2000) 2.60
A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology (1999) 2.51
Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut (2004) 2.48
Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem (1985) 2.47
Doxorubicin gradients in human breast cancer. Clin Cancer Res (1999) 2.36
Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother (2001) 2.35
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer (2002) 2.34
Collagenous colitis and fecal stream diversion. Gastroenterology (1995) 2.32
Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet (1993) 2.22
Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis. J Biol Chem (1984) 2.19
Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem (1991) 2.19
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol (1997) 2.17
Bacterial genome size reduction by experimental evolution. Proc Natl Acad Sci U S A (2005) 2.13
Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J Exp Med (1997) 2.11
Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol (1994) 2.07
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
Nasal continuous positive airway pressure in stroke patients with sleep apnoea: a randomized treatment study. Eur Respir J (2001) 1.97
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol (1994) 1.97
The liver in adolescents with alpha 1-antitrypsin deficiency. Hepatology (1995) 1.95
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol (2001) 1.94
Ribonucleotide reductase from calf thymus. Purification and properties. Biochemistry (1979) 1.90
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol (2004) 1.85
Trapped antihydrogen. Nature (2010) 1.85
Systematic review: microscopic colitis. Aliment Pharmacol Ther (2006) 1.81
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Ribonucleotide reductase from calf thymus. Separation of the enzyme into two nonidentical subunits, proteins M1 and M2. J Biol Chem (1980) 1.78
Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer (1991) 1.77
Allosteric regulation of calf thymus ribonucleoside diphosphate reductase. Biochemistry (1979) 1.76
Liver disease in adults with alpha-1 -antitrypsin deficiency. N Engl J Med (1972) 1.75
Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors. Immunity (1999) 1.75
Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res (1997) 1.74
Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res (1996) 1.74
Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp Cell Res (1983) 1.74
Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther (1990) 1.73
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res (1999) 1.72
Hypoglycaemia associated with the production of insulin-like growth factor II and insulin-like growth factor binding protein 6 by a haemangiopericytoma. Clin Endocrinol (Oxf) (1999) 1.70
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer (2008) 1.69
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann Oncol (1992) 1.68
Paclitaxel-induced neuropathy. Ann Oncol (1995) 1.65
Collagenous colitis in Orebro, Sweden, an epidemiological study 1984-1993. Gut (1995) 1.64
Familial occurrence of microscopic colitis: a report on five families. Scand J Gastroenterol (2001) 1.64
Taxanes: a new class of antitumor agents. Cancer Invest (1995) 1.62
The comet assay: mechanisms and technical considerations. Mutat Res (1996) 1.62
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet (1991) 1.60
MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A (1999) 1.59
Blunted adrenocorticotropin and increased adrenal steroid response to human corticotropin-releasing hormone in Alzheimer's disease. Biol Psychiatry (1996) 1.56
The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs (1998) 1.56
Carcinoma and possible precancerous changes of the gastric stump after billroth II resection. Gastroenterology (1977) 1.56
Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria--an epidemiological investigation. Br J Cancer (1984) 1.56
Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut (2004) 1.56
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Liver, lung and malignant disease in heterozygous (Pi MZ) alpha1-antitrypsin deficiency. Acta Med Scand (1975) 1.55
Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol (1988) 1.54
Ribonucleoside diphosphate reductase from Escherichia coli. An immunological assay and a novel purification from an overproducing strain lysogenic for phage lambdadnrd. J Biol Chem (1977) 1.52
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol (1993) 1.51
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer (1999) 1.50
Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst (1988) 1.50
Studies in vitro on the uptake and degradation of sodium hyaluronate in rat liver endothelial cells. Biochem J (1984) 1.50
Ribonucleoside diphosphate reductase (Escherichia coli). Methods Enzymol (1978) 1.49
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer (2010) 1.49
Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol (1995) 1.49
Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia (1996) 1.47
Obstructive lung disease and trypsin inhibitors in alpha-1-antitrypsin deficiency. Scand J Clin Lab Invest (1967) 1.46
Deoxycytidine kinase is constitutively expressed in human lymphocytes: consequences for compartmentation effects, unscheduled DNA synthesis, and viral replication in resting cells. Exp Cell Res (1988) 1.45
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer (1991) 1.44
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia (1999) 1.44
Hepatitis C in chronic liver disease: an epidemiological study based on 566 consecutive patients undergoing liver biopsy during a 10-year period. J Intern Med (1992) 1.44
Hepatocyte inclusions of alpha 1-antichymotrypsin in a patient with partial deficiency of alpha 1-antichymotrypsin and chronic liver disease. Histopathology (1990) 1.44
Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol (1997) 1.44